EGFR and pachyonychia congenita: Among the many promising factors from several key signaling pathways, we identified a novel mechanistic involvement of EGFR and NF-κB in the MYB signaling which needs to be further explored, particularly in the context of therapeutic targeting of MYB signaling in PC patients.